Abstract
Switching from the concept of substance or alcohol dependence to that of addiction has profoundly modified our ways of approaching, treating and organizing the care of this disease. This more complex and subtle approach gives less importance to the substance and its effects and focuses more on the initiation of pathological behavior. It is important to keep in mind that the addictive process associates a substance (more or less addictive), an individual (more or less vulnerable) and an environment (more or less condoning). Today, it is no longer possible to consider that a drug acts on only one receptor or one system. Current understanding of inner regulation mechanisms integrates the interactions between the various stimulated brain pathways. Addiction treatments which should benefit from advances in genetics, neuropsychology and neuroimaging could be increasingly individualized in the years to come. The “addictology” approach has triggered thinking about other therapeutic approaches such as modification of therapeutic objectives toward “risk reductions” or applying this model to behavioral addictions (food, sex, sport, gaming…)
Keywords: Addiction, individual vulnerability, behavioural, environment, DSM-V, neuropsychology, neuroimaging, addictology, vulnerable, polysubstance, epigenetic, psychology, acetylcholine, neurokinine, glutamate, medications, diagnostic, pertinent, polymorphisms
Current Pharmaceutical Design
Title: From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?
Volume: 17 Issue: 14
Author(s): Michel Reynaud and Laurent Karila
Affiliation:
Keywords: Addiction, individual vulnerability, behavioural, environment, DSM-V, neuropsychology, neuroimaging, addictology, vulnerable, polysubstance, epigenetic, psychology, acetylcholine, neurokinine, glutamate, medications, diagnostic, pertinent, polymorphisms
Abstract: Switching from the concept of substance or alcohol dependence to that of addiction has profoundly modified our ways of approaching, treating and organizing the care of this disease. This more complex and subtle approach gives less importance to the substance and its effects and focuses more on the initiation of pathological behavior. It is important to keep in mind that the addictive process associates a substance (more or less addictive), an individual (more or less vulnerable) and an environment (more or less condoning). Today, it is no longer possible to consider that a drug acts on only one receptor or one system. Current understanding of inner regulation mechanisms integrates the interactions between the various stimulated brain pathways. Addiction treatments which should benefit from advances in genetics, neuropsychology and neuroimaging could be increasingly individualized in the years to come. The “addictology” approach has triggered thinking about other therapeutic approaches such as modification of therapeutic objectives toward “risk reductions” or applying this model to behavioral addictions (food, sex, sport, gaming…)
Export Options
About this article
Cite this article as:
Reynaud Michel and Karila Laurent, From Substance Dependence to Addiction: Impact of a Conceptual Shift on Therapeutic Approaches?, Current Pharmaceutical Design 2011; 17 (14) . https://dx.doi.org/10.2174/138161211796150800
DOI https://dx.doi.org/10.2174/138161211796150800 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Quantifying Risk: The Role of Absolute and Relative Measures in Interpreting Risk of Adverse Reactions from Product Labels of Antipsychotic Medications
Current Drug Safety Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Recent Trends in Design and Developments of New Drugs for the Treatment of Cancer, Rheumatoid arthritis, and Parkinson’s Disease-Associated to Abnormal Signal Transduction
Current Signal Transduction Therapy Neuroprotective Methodologies of Co-Enzyme Q10 Mediated Brain Hemorrhagic Treatment: Clinical and Pre-Clinical Findings
CNS & Neurological Disorders - Drug Targets Message from Editor-in-Chief
CNS & Neurological Disorders - Drug Targets A Case of Topiramate-Induced Epistaxis
Current Drug Safety Clinical Profile of Relaxin, a Possible New Drug for Human Use
Current Drug Safety Naturally Occurring Phenylethanoid Glycosides: Potential Leads for New Therapeutics
Current Medicinal Chemistry Mouse Models of Primary Sjogren’s Syndrome
Current Pharmaceutical Design Bio-Antioxidants – A Chemical Base of Their Antioxidant Activity and Beneficial Effect on Human Health
Current Medicinal Chemistry The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening
Current Drug Safety β-Adrenergic Over-Stimulation and Cardio-Myocyte Apoptosis: Two Receptors, One Organelle, Two Fates?
Current Drug Targets Antenatal Glucocorticoids Supplementation and Central Nervous System Development
Current Drug Metabolism Prognostic Value of Cystatin C in Acute Ischemic Stroke Patients with Intravenous Thrombolysis
Current Neurovascular Research Editorial [Abnormal Bleeding or Bruising Associated with Antiepileptic Treatment]
Current Drug Safety Editorial: [Hot Topic: Genome-Wide Analysis of Drug Action]
Current Psychopharmacology Central Actions of Somatostatin-28 and Oligosomatostatin Agonists to Prevent Components of the Endocrine, Autonomic and Visceral Responses to Stress Through Interaction with Different Somatostatin Receptor Subtypes
Current Pharmaceutical Design Mitochondrial Toxins in Basal Ganglia Disorders: From Animal Models to Therapeutic Strategies
Current Neuropharmacology Antioxidant Activities of Retinoidal Benzimidazole Or Indole Derivatives in In Vitro Model Systems
Current Medicinal Chemistry